Phosphagenics Limited (POH) has signed an agreement appointing Pulse Pharmacies as its exclusive Australia-wide distributer of Phosphagenics’ new Elixia™ skincare product range.
The Elixia™ range of six products, including an Anti-oxidant Serum and a Multi V Moisturiser, uses the Phosphagenics patented TPM™ (Targeted Penetration Matrix) delivery technology to deliver more active ingredients into the skin.
According to Phosphagenics’ Chief Operating Officer, Dr Esra Ogru, the patented TPM™ delivery technology has demonstrated in many human clinical trials that it can increase the amount and depth of penetration of active molecules into the skin including drugs such as insulin and opioids. “The technology lends itself perfectly to skin care, and the inclusion of TPM™ within the Elixia range will increase the absorption of active ingredients used in the cosmetic industry, compared to other marketed topical applications.” She added, “Elixia™ will take advantage of TPM’s scientifically proven ability to increase the absorption of valuable molecules from our vitamin-rich formulas. While comparator products may contain similar ingredients, we know TPM™ will ensure they don’t sit on the skin surface and will reach the layers of skin that will benefit from their activity.”
The Elixia™ skincare range is expected to be available for purchase from the end of March in 75 Pulse Pharmacies, Vitamin Me and Roy Young stores nationally, as well as online. A dedicated website designed for customers to access the brand (www.elixia.com.au) will offer product information, skincare tips and highlight launch activities and promotions.
“The Elixia™ products have clear superiority and Pulse Pharmacies always relishes being able to offer our customers the best available,” said Mr Rohan Aujard, Chief Executive Officer of Pulse Pharmacy.
Phosphagenics is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM™ – Targeted Penetration Matrix technology. TPM™ is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products. The two product targets which are advancing through clinical trials are an insulin patch for diabetics (instead of injections) and an oxycodone patch for the relief of chronic pain.
www.phosphagenics.com
